A Seeking Alpha article said to keep an eye on Dendreon Corp. (Nasdaq: DNDN) as European regulators prepare for a final decision on the company’s prostate cancer treatment Provenge. The biotechnology firm will also report second quarter earnings later this week. The stock price gained 60 cents to $5.20.
Monitor Dendreon
August 05, 2013 at 06:20 AM EDT